Results 161 to 170 of about 659,948 (302)
Abstract Background Emerging evidence implicates neuroinflammation in progressive supranuclear palsy (PSP) pathophysiology, with elevated cyto‐chemokines suggesting natural killer (NK) cell involvement. Methods We characterized peripheral NK in PSP (N = 11) versus Parkinson's disease (PD, N = 10) and healthy controls (HC, N = 8) at both ...
Marina Picillo +11 more
wiley +1 more source
Abstract Background Blood–brain barrier disruption is increasingly recognized in synucleinopathies, but the role of the endothelial glycocalyx (GLX) in Parkinson's disease (PD) and multiple system atrophy (MSA) remains unclear. Objectives The aim was to determine whether plasma GLX markers differ between PD, MSA, and healthy controls (HC), relate to ...
Jonas Folke +15 more
wiley +1 more source
Atrophy signature for alpha-synuclein copathology in Alzheimer's disease. [PDF]
Esteller-Gauxax D +17 more
europepmc +1 more source
Abstract Background The GBA1 gene encodes the lysosomal enzyme glucocerebrosidase (GCase). Parkinson's disease (PD) patients carrying a GBA1 variant (GBA‐PD) exhibit faster cognitive decline, linked to cholinergic degeneration. Objectives The aim was to investigate whether GCase activity, measured in monocytes, correlates with cognitive dysfunction or ...
Sofie Slingerland +8 more
wiley +1 more source
Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice
Mutation A30P in the alpha-synuclein gene is a cause of familial Parkinson disease. Transgenic mice expressing wild mouse and mutant human A30P alpha-synuclein, Tg5093 mice (Tg), show a progressive motor disorder characterized by tremor, rigidity, and ...
Cuadrado-Tejedor, M. (Mar) +3 more
core
Abstract Background Common and rare genetic variants in leucine‐rich repeat kinase 2 (LRRK2) have been linked with sporadic and familial Parkinson's disease (PD). Recently, we discovered that common genetic variation near the LRRK2 locus determined survival in progressive supranuclear palsy (PSP).
Louise‐Kristine Nielsen +27 more
wiley +1 more source
Abstract Background [18F]Fluorodeoxyglucose positron emission tomography ([18F]FDG PET) represents an endorsed neurodegeneration biomarker in neuronal α‐synucleinopathies. Idiopathic/isolated rapid eye movement (REM) sleep behavior disorder (iRBD) represents a prodromal stage of such disorders.
Beatrice Orso +15 more
wiley +1 more source
Molecular profiling of alpha-synuclein pathology and seeding activity in Parkinson's disease. [PDF]
Kaya ZB +10 more
europepmc +1 more source
PREDICT‐PD: A Two‐Stage Approach to Early Identification of Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.
Sasivimol Virameteekul +9 more
wiley +1 more source
Abstract Background Leucine‐rich repeat kinase 2 (LRRK2) kinase inhibition is a promising therapeutic strategy for Parkinson's disease (PD), but the functional impact of Asian‐prevalent LRRK2 p.G2385R and p.R1628P variants remains unclear. Robust patient stratification and target engagement markers are needed for global LRRK2‐targeted trials ...
Tzi Shin Toh +17 more
wiley +1 more source

